



Join Keystone Symposia
for the 2016 conference on:

Antibodies as Drugs

March 6–10, 2016

Fairmont Chateau Whistler | Whistler, British Columbia | Canada

Scientific Organizers:

Peter D. Senter, Anna M. Wu, Alan J. Korman and Karl Dane Wittrup

Joint with the conference on

Cancer Vaccines Targeting Cancer Genes for Immunotherapy

This meeting will focus attention on many of the key advances in antibody-based technologies as well as on where the field is heading. Some of the critical topics to be covered include: 1) Antibody structure and function; 2) Engineered antibodies and antibody-like molecules for improved efficacy; 3) Antibody pharmacologic properties and biologic distribution; 4) Antibody-based therapies for cancer and infectious diseases; 5) Targeting costimulatory pathways and immunological checkpoints; 6) Antibodies as carriers of drugs, cytokines, radioisotopes and imaging agents; 7) Antibody mimetics; 8) Clinical advancements and challenges. This meeting has become an established forum that attracts both new investigators and leaders in the field, coming from academia, industry and research institutes around the globe. The goals of the meeting will be to address the critical issues facing the broad field of antibody-based therapeutics, provide an overview of recent advances and bring together interdisciplinary groups for the generation of new ideas and promising areas of investigation.

Session Topics:

- Getting Antibodies to Where They Need to Go
- Engineering Antibody Function
- B Cell Biology and Antibody Repertoires
- Novel Antibody Constructs
- Targeted Delivery for Imaging and Therapy
- Antibodies for Checkpoint Blockade (Joint)
- Antibodies as Co-Factors (Joint)
- Antibodies for the Treatment of Infectious Diseases



Submitting an abstract is a great way of participating in the conference through poster presentation and possible selection for a short talk.

Scholarship & Discounted Abstract Deadline: Nov 5, 2015

Abstract Deadline: Dec 8, 2015

Discounted Registration Deadline: Jan 7, 2016

For additional details, visit www.keystonesymposia.org/16X2.

KEYSTONE SYMPOSIA™
on Molecular and Cellular Biology
Accelerating Life Science Discovery

www.keystonesymposia.org/meetings | 1.800.253.0685 | 1.970.262.1230

a 501(c)(3) nonprofit educational organization

KEYSTONE SYMPOSIA

on Molecular and Cellular Biology

Antibodies as Drugs (X2)

Scientific Organizers: Peter D. Senter, Anna M. Wu, Alan J. Korman and Karl Dane Wittrup

Sponsored by Genentech, Inc., Genmab A/S, ImmunoGen, Inc., Mersana Therapeutics, MorphoSys AG, OncoMed Pharmaceuticals, Inc. and Regeneron Pharmaceuticals, Inc.

Cancer Vaccines: Targeting Cancer Genes for Immunotherapy (X1)

Scientific Organizers: A. Karolina Palucka, Hyam I. Levitsky and Laurence Zitvogel

March 6-10, 2016 • Fairmont Chateau Whistler • Whistler, British Columbia, Canada

Sponsored by Regeneron Pharmaceuticals, Inc.

Abstract & Scholarship Deadline: November 5, 2015 / Abstract Deadline: December 8, 2015 / Discounted Registration Deadline: January 7, 2016

SUNDAY, MARCH 6

Arrival and Registration

MONDAY, MARCH 7

Welcome and Keynote Session (X2)

*Peter D. Senter, Seattle Genetics Inc., USA

Rakesh K. Jain, Massachusetts General Hospital and Harvard Medical School, USA

Reengineering the Tumor Microenvironment to Enhance Cancer Treatment: Bench to Bedside

Andreas G. Plückthun, University of Zürich, Switzerland
Protein Engineering Approaches to New Biologicals

Welcome and Keynote Session (X1)

*A. Karolina Palucka, The Jackson Laboratory for Genomic Medicine, USA

Ronald N. Germain, NIAID, National Institutes of Health, USA
Visualizing and Deconstructing Immune Responses in situ

Sebastian Amigorena, Institut Curie, France
Regulation of Antigen Cross Presentation and Anti Tumor Immune Responses

Getting Antibodies to Where They Need to Go (X2)

*Peter D. Senter, Seattle Genetics Inc., USA

James M. Olson, Fred Hutchinson Cancer Research Center, USA
Micro Needle Technologies for Intratumoral Drug Delivery and Combination Screening

Alison M. Betts, Pfizer, Inc., USA
PK/PD Modeling for Macromolecular Drug Delivery

Richard Tavaré, University of California, Los Angeles, USA
Short Talk: Noninvasive Detection of Tumor-Infiltrating Lymphocytes using Anti-CD8 Immuno-PET: Impact of Protein Dose

Antigens (X1)

*A. Karolina Palucka, The Jackson Laboratory for Genomic Medicine, USA

Cornelis J. M. Melief, Leiden University Medical Center & ISA Pharmaceuticals BV, Netherlands
Synergy of Therapeutic Vaccination against HPV16 Oncogenic Proteins and Standard Chemotherapeutics

Victor H. Engelhard, University of Virginia, USA
Phosphopeptides Displayed by MHC Molecules as New-Generation Cancer Vaccine Targets

Poster Session 1

Workshop 1: Novel Constructs (X2)

*Dennis R. Benjamin, Seattle Genetics Inc., USA

Jonathan H. Davis, Bristol-Myers Squibb, USA

Synergy Generates Picomolar Potency and a High Resistance Barrier in Combivectin, a Novel Trispecific HIV-1 Entry Inhibitor with Clinical Promise

Eric Hatterer, NovImmune.SA, Switzerland

Characterizing the Preclinical Candidate, NI-1701, a CD47 Targeting Bispecific Antibody in Development for the Treatment of B Cell Lymphomas and Leukemias

Paul A. Moore, MacroGenics, USA

MGD009, a B7-H3 x CD3 Bispecific Dual-Affinity Re-Targeting (DART®) Molecule Directing T Cells to Solid Tumors

Marijn A. Gillissen, Aim Therapeutics / AMC, Netherlands
Donor-Derived B Cells Produce Potent AML-Specific Antibodies that Recognize a Novel Tumor-Specific Antigen and Mediate Graft-Versus-Leukemia Immunity

Yu-Sang Sabrina Yang, Massachusetts Institute of Technology, USA
Targeting Immunomodulators to Lymphocytes Via Amphiphilic Gold Nanocarriers

Travis Young, California Institute for Biomedical Research, USA
Antibody-based Control of CAR-T Cell Therapy

Workshop 1: Molecular Vaccines (X1)

*Darrell J. Irvine, Massachusetts Institute of Technology, USA

*Yvette van Kooyk, Vrije University Medical Center, Netherlands

Tomasz Ahrends, Netherlands Cancer Institute, Netherlands
Combined CD27-Costimulation and PD-1-Inhibition Recapitulates CD4+ T-cell Help in Therapeutic Vaccination Against Cancer

Suresh de Silva, Heat Biologics Inc., USA
Combination Immunotherapy: T-cell Costimulation (OX40L, TL1A, 4-1BBL and ICOSL) Secreted Locally by Gp96-Ig Vaccines, Elicits Robust Antigen-Specific, Memory T Cell Responses and Tumor Elimination

Christa I. DeVette, University of Oklahoma Health Sciences Center, USA
Development of Tools to Evaluate Anti-tumor Immunity

James Moon, University of Michigan, USA
Nanodisc-Based Peptide Vaccines for Personalized Cancer Immunotherapy

Geoffrey Lynn, National Institutes of Health, USA
Self-Assembling Nanoparticles Codelivering Peptide Neoantigens and TLR-7/8 Agonists Enhance the Breadth and Potency of Anti-Tumor Immunity

Naveen Mehta, Massachusetts Institute of Technology, USA
Utilizing Protein Carriers to Engineer Cancer Vaccines with Improved Potency

Kristen Radford, University of Queensland, Australia
Targeting Antigen to Human CD141+ Dendritic Cells via CLEC9A in vitro and in vivo Confers Effective Cross-Presentation to CD8+ T Cells

KEYSTONE SYMPOSIA

on Molecular and Cellular Biology

Antibodies as Drugs (X2)

Scientific Organizers: Peter D. Senter, Anna M. Wu, Alan J. Korman and Karl Dane Wittrup

Sponsored by Genentech, Inc., Genmab A/S, ImmunoGen, Inc., Mersana Therapeutics, MorphoSys AG, OncoMed Pharmaceuticals, Inc. and Regeneron Pharmaceuticals, Inc.

Cancer Vaccines: Targeting Cancer Genes for Immunotherapy (X1)

Scientific Organizers: A. Karolina Palucka, Hyam I. Levitsky and Laurence Zitvogel

March 6-10, 2016 • Fairmont Chateau Whistler • Whistler, British Columbia, Canada

Sponsored by Regeneron Pharmaceuticals, Inc.

Abstract & Scholarship Deadline: November 5, 2015 / Abstract Deadline: December 8, 2015 / Discounted Registration Deadline: January 7, 2016

Engineering Antibody Function (X2)

***Alison M. Betts**, Pfizer, Inc., USA

Margaret Ellen Ackerman, Dartmouth College, USA
Evolution of Antibodies for Optimized Effector Function Activities

Jeanette H.W. Leusen, University Medical Center Utrecht, Netherlands

IgA as Alternative Therapeutic Antibody: Combination with IgG, Half-Life Extension and More

Sarel J. Fleishman, Weizmann Institute of Science, Israel
De novo Design of Novel Protein Functions

Paul W. H. I. Parren, Leiden University Medical Center, Netherlands
Functional Aspects of Antigen- and Fc-Dependent IgG Hexamer Formation

Antigen-Presenting Cells (X1)

***Jacques F. Banchereau**, The Jackson Laboratory for Genomic Medicine, USA

Julie Magarian Blander, Weill Cornell Medicine, Cornell University, USA
Regulation of Antigen Cross-presentation in Dendritic Cells

A. Karolina Palucka, The Jackson Laboratory for Genomic Medicine, USA
Dendritic Cells as Cancer Vaccines

Matthew F. Krummel, University of California, San Francisco, USA
T Cell-Antigen Presenting Dynamics in the Tumor Microenvironment

Brian J. Francica, Aduro Biotech, USA
Short Talk: Radio-resistant Stromal Cells Initiate the Innate Response to Cyclic Dinucleotides

TUESDAY, MARCH 8

B Cell Biology and Antibody Repertoires (X2)

***David A. Scheinberg**, Memorial Sloan Kettering Cancer Center, USA

George Georgiou, University of Texas at Austin, USA
Systematic Characterization and Comparative Analysis of Antibody Repertoires

Pavel Tolar, Francis Crick Institute, UK
EMBO Young Investigator Lecture: Regulation of Antibody Responses by B Cell Mechanical Activity

Laura M. Walker, Adimab LLC, USA
Rapid and Large-Scale Isolation of Potent Neutralizing Antibodies from a Survivor of the 2014 Ebola Virus Outbreak

Paul A. Ramsland, RMIT University, Australia
Short Talk: Unanticipated Global Changes in IgG1 from Mutation of FcRn Binding Site Residues

Sai T. Reddy, ETH Zurich, Switzerland
Short Talk: Correlations of Antibody Response Phenotype to Genotype Revealed by Molecular Amplification Fingerprinting

Priming Effector T Cells (X1)

***Sebastian Amigorena**, Institut Curie, France

Victor Appay, INSERM U1135 - CIMI, France
Impaired Induction of High-Quality Effector CD8+ T-Cells in Old Humans

Luca Gattinoni, NCI, National Institutes of Health, USA
Generation of Long-Lived Cancer Antigen-Specific CD8+ T Cell Memory

Pamela S. Ohashi, Princess Margaret Cancer Centre, Canada
Novel Subsets Involved in T Cell Anti-Tumor Immunity

Ugur Sahin, BioNTech AG, Germany
Exploiting Antiviral Immune Mechanisms for Cancer Immunotherapy

Dixon Dorand, Case Western Reserve University, USA
Short Talk: Cyclin Dependent Kinase 5 (CDK5) Controls PD-L1 Expression via Phosphorylation of IRF2BP2 in Murine Medulloblastoma and CDK5 Deficiency Results in CD4+ Dependent T-Cell Rejection

Alison Taylor, University of Cambridge, UK
Short Talk: Glycogen Synthase Kinase 3 Inhibition Blocks PD-1 Expression via Increased Tbet Expression for Enhanced CD8+ Cytolytic T-Cell Responses

Workshop 2: Cell-Based Vaccines (X1)

***Robert A. Seder**, NIAID, National Institutes of Health, USA

***Masaki Terabe**, NCI, National Institutes of Health, USA

Andres Alloatti, Institut Curie, France
Dissecting Cross-Presentation in Dendritic Cells: Who, How and Why?

Anja C. Bloom, NCI, National Institutes of Health, USA
INT230-6 Administered Intratumorally Converts Tumor to an Endogenous Vaccine in Mouse Colon Cancer

Agamemnon Antoniou Epenetos, Imperial College London, UK
Creation of Biological Microparticles from Mesenchymal Stem Cell (MSC) to Deliver Vaccines and other Therapeutics such as Proteins or Nucleic Acids

Simon Heidegger, Klinikum Rechts der Isar, Technical University Munich, Germany
Activation of the Cytosolic RNA Receptor RIG-I in Tumor and Immune Cells Triggers Efficient Anti-Tumor Immunity and Synergizes with Checkpoint Blockade

Kavya Rakhra, Massachusetts Institute of Technology, USA
Combination Immunotherapy of an Autochthonous Murine Lung Cancer Model Expressing Human CEA as a Tumor-Associated Self-Antigen

Yvette van Kooyk, Vrije University Medical Center, Netherlands
Vaccines Facilitating Cross-Presentation for the Induction of Tumor-Immunity Overcoming Tumor Induced Suppression

KEYSTONE SYMPOSIA

on Molecular and Cellular Biology

Antibodies as Drugs (X2)

Scientific Organizers: Peter D. Senter, Anna M. Wu, Alan J. Korman and Karl Dane Wittrup

Sponsored by Genentech, Inc., Genmab A/S, ImmunoGen, Inc., Mersana Therapeutics, MorphoSys AG, OncoMed Pharmaceuticals, Inc. and Regeneron Pharmaceuticals, Inc.

Cancer Vaccines: Targeting Cancer Genes for Immunotherapy (X1)

Scientific Organizers: A. Karolina Palucka, Hyam I. Levitsky and Laurence Zitvogel

March 6-10, 2016 • Fairmont Chateau Whistler • Whistler, British Columbia, Canada

Sponsored by Regeneron Pharmaceuticals, Inc.

Abstract & Scholarship Deadline: November 5, 2015 / Abstract Deadline: December 8, 2015 / Discounted Registration Deadline: January 7, 2016

Megan C. Wise, Inovio Pharmaceuticals, USA
Various forms of CD40L Encoded as an Immune Plasmid Adjuvant Generate Unique Anti-HPV DNA Vaccine Induced Responses

Novel Antibody Constructs (X2)

***Anna M. Wu**, University of California, Los Angeles, USA
David A. Scheinberg, Memorial Sloan Kettering Cancer Center, USA
Drugging Intracellular Targets with Vaccines and Human Therapeutic TCR Mimic Antibodies
Dennis R. Benjamin, Seattle Genetics Inc., USA
Antibody Drug Conjugates for Cancer Therapy
Birgit Schoeberl, Novartis Institutes for BioMedical Research, USA
Multispecific Antibody Therapeutics Derived from Systems Biology and Computational Modeling
John C. Williams, Beckman Research Institute at City of Hope, USA
Functionalization of MAbs Using Mechanical Bonds

Reprogramming T Cell Memory (X1)

***Victor Appay**, INSERM U1135 - CIMI, France
Rafi Ahmed, Emory University School of Medicine, USA
Features of Memory CD8+ T Cells in Chronic Infection
Nicholas P. Restifo, NCI, National Institutes of Health, USA
Lineage Relationship of Effector and Memory T Cells
Jonathan D. Powell, Johns Hopkins University School of Medicine, USA
Targeting Immunometabolism as a Means of Enhancing Immunotherapy
Madhusudhanan Sukumar, NCI, National Institutes of Health, USA
Short Talk: Mitochondrial Membrane Potential Identifies Cells with Enhanced Stemness for TCR and CAR based Adoptive Immunotherapy of Cancer

Poster Session 2

WEDNESDAY, MARCH 9

Targeted Delivery for Imaging and Therapy (X2)

***Alan J. Korman**, Bristol-Myers Squibb, USA
Anna M. Wu, University of California, Los Angeles, USA
Detecting Tumor and Immune Cell Responses to Therapy Using ImmunoPET
Katherine A. Vallis, University of Oxford, UK
Antibody-Based Radiotherapy and Radiodetection of Cancer
Colin E. Correnti, Fred Hutchinson Cancer Research Center, USA
Tumor Paint and Penetrating Peptide Drug Conjugates
Jacob Petersburg, University of Minnesota, USA
Short Talk: Utilizing Prosthetic Antigen Receptors (PARs) for Anti-EpCAM Cell-directed Immunotherapy
David T. Rodgers, Calibr, USA
Short Talk: Antibody Based Switches Control the Activation and Targeting of CAR T Cells for B Cell Malignancies

Cancer Vaccines (X1)

***Cornelis J. M. Melief**, Leiden University Medical Center & ISA Pharmaceuticals BV, Netherlands
Laurence Zitvogel, Institut Gustave Roussy, France
Molecular Mechanisms of Cancer Antigen Presentation at the Tumor Site
Thomas W. Dubensky, Jr., Tempest Therapeutics, USA
*Insights from *Listeria monocytogenes* for the Development of Vector- and Small Molecule-Based Cancer Immunotherapy Strategies*
Howard L. Kaufman, Replimune Group Inc, USA
Advances in Oncolytic Virus Immunotherapy
Sandra Demaria, Weill Cornell Medical College, USA
In situ Vaccination by Radiation Therapy
Rupert Kenefeck, Immunocore Ltd., UK
Short Talk: Overcoming Immune Regulation to Kill Cancers: ImmTAC Targeting and Checkpoint Inhibition

Workshop 2: Novel Designs and Therapeutics (X2)

***Margaret Ellen Ackerman**, Dartmouth College, USA
Hamid Bassiri, Children's Hospital of Philadelphia, USA
Novel Invariant Natural Killer T Cell-Based Immunotherapies for Cancer
Hanke Matlung, Sanquin Research and Landsteiner Laboratory, Netherlands
Neutrophils Kill Antibody-Opsonized Cancer Cells by Trogoptosis
Sheena N. Smith, University of Zurich, Switzerland
Targeted Adenoviral Delivery of Protein-Based Therapeutics to the Tumor Microenvironment
Michael W. Munks, Oregon Health & Science University, USA
Major Histocompatibility Class I - Antibody Fusion Proteins (pMHC-IgGs) that Link B16 Melanoma Cells to Cytomegalovirus-Specific CD8 T Cells Control B16 Melanoma in vivo
Huafeng Xu, D.E. Shaw Research LLC, USA
Divergent Sequences Stabilize Similar Antigen-Binding Conformations in the Affinity Maturation of a Broadly Neutralizing Influenza Antibody Lineage
David P. Humphreys, UCB Pharma, UK, UK
Statistical Design for Effector Function Engineering of Hexameric Fc Domains
Andre BH Choo, Bioprocessing Technology Institute, Singapore
Glycan: A Sweet Opportunity for Antibody Discovery

Antibodies for Checkpoint Blockade (Joint)

***Madhav V. Dhodapkar**, Yale School of Medicine, USA
Alan J. Korman, Bristol-Myers Squibb, USA
Antitumor Activity of Immunomodulatory Antibodies

KEYSTONE SYMPOSIA

on Molecular and Cellular Biology

Antibodies as Drugs (X2)

Scientific Organizers: Peter D. Senter, Anna M. Wu, Alan J. Korman and Karl Dane Wittrup

Sponsored by Genentech, Inc., Genmab A/S, ImmunoGen, Inc., Mersana Therapeutics, MorphoSys AG, OncoMed Pharmaceuticals, Inc. and Regeneron Pharmaceuticals, Inc.

Cancer Vaccines: Targeting Cancer Genes for Immunotherapy (X1)

Scientific Organizers: A. Karolina Palucka, Hyam I. Levitsky and Laurence Zitvogel

March 6-10, 2016 • Fairmont Chateau Whistler • Whistler, British Columbia, Canada

Sponsored by Regeneron Pharmaceuticals, Inc.

Abstract & Scholarship Deadline: November 5, 2015 / Abstract Deadline: December 8, 2015 / Discounted Registration Deadline: January 7, 2016

KEYSTONE SYMPOSIA

on Molecular and Cellular Biology

Antibodies as Drugs (X2)

Scientific Organizers: Peter D. Senter, Anna M. Wu, Alan J. Korman and Karl Dane Wittrup

Sponsored by Genentech, Inc., Genmab A/S, ImmunoGen, Inc., Mersana Therapeutics, MorphoSys AG, OncoMed Pharmaceuticals, Inc. and Regeneron Pharmaceuticals, Inc.

Cancer Vaccines: Targeting Cancer Genes for Immunotherapy (X1)

Scientific Organizers: A. Karolina Palucka, Hyam I. Levitsky and Laurence Zitvogel

March 6-10, 2016 • Fairmont Chateau Whistler • Whistler, British Columbia, Canada

Sponsored by Regeneron Pharmaceuticals, Inc.

Abstract & Scholarship Deadline: November 5, 2015 / Abstract Deadline: December 8, 2015 / Discounted Registration Deadline: January 7, 2016

Suzanne L. Topalian, Johns Hopkins University School of Medicine, USA

PD-1 Blockade in Cancer Therapy: Mechanism-Based Biomarkers and New Frontiers

John J. Miles, QIMR Berghofer Medical Research Institute, Australia
CD96/TIGIT/DNAM Pathway and Tumor Rejection

Poster Session 3

THURSDAY, MARCH 10

Antibodies as Co-Factors (Joint)

***Laurence Zitvogel**, Institut Gustave Roussy, France

Madhav V. Dhodapkar, Yale School of Medicine, USA
Harnessing Host Response to Premalignancy in Prevention of Cancer

Carl G. Figdor, Radboud University Medical Center, Netherlands
Dendritic Cell Based Cancer Immunotherapy

Ira Mellman, Genentech, Inc., USA
The Mechanistic Basis of Cancer Immunotherapy

Nina Bhardwaj, Icahn School of Medicine at Mount Sinai, USA
Modulation of Innate Immunity in Cancer

Kelly D. Moynihan, Third Rock Ventures, USA
Short Talk: Eradication of Large Established Tumors by Combination Immunotherapy Engaging Innate and Adaptive Immunity

Rony Dahan, Rockefeller University, USA
Short Talk: Improved Therapeutic Activity of Agonistic, Human Anti-CD40 Monoclonal Abs by Selective FcγR-Engagement

Workshop 3: Peptides as Vaccines (X1)

***Robert D. Schreiber**, Washington University School of Medicine, USA

Anne-Mette Bjerregaard, Technical University of Denmark, Denmark
MuPeXI: A Tool for Prediction of Neo-Epitopes from Tumor Sequencing Data

Gustav Gaudernack, Ultimovacs AS/Norwegian Radium Hospital, Norway
UV1 – A Second-Generation, Peptide-Based, Therapeutic Cancer Vaccine (TCV) Targeting the Reverse Transcriptase Subunit of Human Telomerase (hTERT)

Matthew M. Gubin, Washington University in St. Louis, USA
Tumor-Specific Mutant Antigens in Cancer Immunotherapy

Bruno Laugel, Institut De Recherche Servier, France
Safety Assessment of DNA Methyl Transferase Inhibitors in Combination with NY-ESO T-cell Therapy.

Aizea Morales Kastresana, NCI, National Institutes of Health, USA
Optimization of Extracellular Vesicle Labels for NanoFACS

Hideho Okada, University of California, San Francisco, USA
Novel and Shared Neoantigen for Glioma T Cell Therapy Derived from Histone 3 Variant H3.3 K27M Mutation

Jeffrey Ward, Washington University School of Medicine, USA
Tumor Mutant Antigen-Specific CD8+ T-cells Require CD4+ T-cell Help to Induce Tumor Regression

Klaus Früh, Oregon Health & Science University, USA
CMV-induced MHC-II and MHC-E-Restricted CD8+ T Cells: A Role in Cancer Immunotherapy

Antibodies for the Treatment of Infectious Diseases (X2)

Leo James, MRC Laboratory of Molecular Biology, UK
Intracellular Antibody Immunity and the Cytosolic Fc Receptor TRIM21

Carole A. Bewley, National Institutes of Health, USA
Antibody-like Properties and Functions of Antiviral Carbohydrate Binding Proteins

Linking Cancer Genetics and Genomics with Immunity (X1)

***Hyam I. Levitsky**, , USA

Jacques F. Banichereau, The Jackson Laboratory for Genomic Medicine, USA
Genomics of Human Immune Response

Robert D. Schreiber, Washington University School of Medicine, USA
Cancer-Specific Mutations as Tumor Rejection Antigens

Catherine Ju-Ying Wu, Dana-Farber Cancer Institute, USA
Targeting Tumor Neoantigens: Developing Personalized Cancer Vaccines

Meeting Wrap-Up: Outcomes and Future Directions (Organizers) (X2)

The Human Vaccines Project: A Roadmap to Effective Cancer Vaccine and Immunotherapeutic Development (X1)

***A. Karolina Palucka**, The Jackson Laboratory for Genomic Medicine, USA

Theodore Schenkelberg, Human Vaccines Project, USA

FRIDAY, MARCH 11

Departure

KEYSTONE SYMPOSIA

on Molecular and Cellular Biology

Antibodies as Drugs (X2)

Scientific Organizers: Peter D. Senter, Anna M. Wu, Alan J. Korman and Karl Dane Wittrup

Sponsored by Genentech, Inc., Genmab A/S, ImmunoGen, Inc., Mersana Therapeutics, MorphoSys AG, OncoMed Pharmaceuticals, Inc. and Regeneron Pharmaceuticals, Inc.

Cancer Vaccines: Targeting Cancer Genes for Immunotherapy (X1)

Scientific Organizers: A. Karolina Palucka, Hyam I. Levitsky and Laurence Zitvogel

March 6-10, 2016 • Fairmont Chateau Whistler • Whistler, British Columbia, Canada

Sponsored by Regeneron Pharmaceuticals, Inc.

Abstract & Scholarship Deadline: November 5, 2015 / Abstract Deadline: December 8, 2015 / Discounted Registration Deadline: January 7, 2016